Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
Open Access
- 21 July 2014
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 525
Abstract
In this retrospective study, the authors evaluated the prognostic value of whole-body total lesion glycolysis (WTLG) on FDG/PET images in metastatic breast cancer (MBC) patients.Keywords
This publication has 23 references indexed in Scilit:
- Volume-based Parameters Measured by Using FDG PET/CT in Patients with Stage I NSCLC Treated with Stereotactic Body Radiation Therapy: Prognostic ValueRadiology, 2014
- Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute studyBreast Cancer Research and Treatment, 2013
- The SUVmax for 18F-FDG Correlates With Molecular Subtype and Survival of Previously Untreated Metastatic Breast CancerClinical Nuclear Medicine, 2013
- The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancerBMC Cancer, 2013
- Prognostic Value of Circulating Tumor Cells According to Immunohistochemically Defined Molecular Subtypes in Advanced Breast CancerClinical Breast Cancer, 2012
- A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatmentsBreast Cancer Research and Treatment, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Maximum Standardized Uptake Value From Staging FDG-PET/CT Does not Predict Treatment Outcome for Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005